NADAC acquisition cost data for PROMETHAZINE 12.5 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 10702000201 | $0.0467 | 2022-12-21 | Rx |
| 53746074501 | $0.0467 | 2022-12-21 | Rx |
| 57664010788 | $0.0467 | 2022-12-21 | Rx |
| 60687066001 | $0.0467 | 2022-12-21 | Rx |
| 60687066011 | $0.0467 | 2022-12-21 | Rx |
| 65162074510 | $0.0467 | 2022-12-21 | Rx |
| 68001016100 | $0.0467 | 2022-12-21 | Rx |
| 68084015401 | $0.0467 | 2022-12-21 | Rx |
| 68084015411 | $0.0467 | 2022-12-21 | Rx |
| 68382004001 | $0.0467 | 2022-12-21 | Rx |
Generic: Promethazine HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.4M | 1,495,922 | 565,436 | $0.3192 |
| 2020 | $17.1M | 1,431,996 | 504,734 | $0.2969 |
| 2021 | $16.5M | 1,417,603 | 515,884 | $0.2772 |
| 2022 | $17.5M | 1,431,004 | 538,484 | $0.2851 |
| 2023 | $16.5M | 1,396,951 | 523,738 | $0.2694 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.